| Summary: | 碩士 === 國立暨南國際大學 === 生物醫學科技研究所 === 93 === Patients with colorectal cancer are usually diagnosed when
tumor cells has been metastased. The metastasis of carcinoma
is not easily eliminated completely by surgery. Interferon-beta
(IFN-b) has been used as an antitumor drug against human glioma,
melanoma and medulloblastoma since 1980s, it acts as an activator
to stimulate immune system to produce specific immune response
against tumor cell growth. We hypothesized that the combination
of IFN-b gene therapy with immunotherapy could increase the
efficacy of cancer therapy. In this study, we tested whether the
combination of IFN-b gene therapy and immunotherapy with tumor
cell lysate-pulsed dendritic cells (DCs) could increase the
efficacy of IFN-b gene therapy. The cloned IFN-b gene was proven
to be expressed in vitro and in vivo. This construct was then
used in the therapy. Our results showed that there is no
significant antitumor effect on the CT26 colorectal cancer
cells-bearing mice treated with either IFN-b gene alone or
IFN-b/DC co-injection. However, IFN-b gene therapy followed
by DC immunotherapy resulted in a significant inhibitory effect
on tumor cell growth and prolonged survival time. It is found
that the antiproliferative effect of IFN-b on CT26 may via the
induction of cell apoptosis. Based on the results, this
combination therapy may be one promising candidate for
colorectal carcinoma therapy in the near future.
|
|---|
